NeuBase Therapeutics, Inc. — Net Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/6048b7b6-fd0f-4019-92cb-9f733152ef2e/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2022 | $-33.8M | 2021-10-01 – 2022-09-30 | evidence 0001410578-22-003576 |
| FY 2021 | $-25.4M | 2020-10-01 – 2021-09-30 | evidence 0001410578-21-000599 |
| FY 2020 | $-17.4M | 2019-10-01 – 2020-09-30 | evidence 0001104659-20-139139 |
| FY 2019 | $-26.1M | 2018-10-01 – 2019-09-30 | evidence 0001104659-20-139139 |
| FY 2018 | $-13.2M | 2017-10-01 – 2018-09-30 | evidence 0001387131-19-000051 |
| FY 2017 | $-23.8M | 2016-10-01 – 2017-09-30 | evidence 0001387131-17-005845 |
| FY 2016 | $-25.8M | 2015-10-01 – 2016-09-30 | evidence 0001387131-16-008696 |
| FY 2015 | $-15.2M | 2014-10-01 – 2015-09-30 | evidence 0001387131-15-003603 |
| FY 2014 | $-9.1M | 2013-10-01 – 2014-09-30 | evidence 0001387131-14-004117 |
| FY 2013 | $-16.5M | 2007-10-01 – 2014-03-31 | evidence 0001387131-14-001860 |
| FY 2012 | $-9.4M | 2007-10-01 – 2013-03-31 | evidence 0001387131-13-001784 |
| FY 2011 | $-6.5M | 2007-10-01 – 2012-03-31 | evidence 0001387131-12-001477 |
| FY 2010 | $494.4k | 2009-10-01 – 2010-09-30 | evidence 0001387131-11-001669 |
| FY 2009 | $-864.4k | 2008-10-01 – 2009-09-30 | evidence 0001387131-12-000055 |
| FY 2008 | $24.8k | 2007-10-01 – 2008-09-30 | evidence 0001387131-12-000055 |
| FY 2007 | $-6.3M | 2006-10-01 – 2007-09-30 | evidence 0001387131-12-000055 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).